Carlyle Group LP, a global alternative asset manager, bought a "significant" minority stake in biotechnology company Ambio Holdings Inc. from MVM Partners LLP, a healthcare-focused private equity firm.
Carlyle made the acquisition in Ambio, which produces peptides for drugs approved by U.S., Chinese and European agencies, via its Carlyle Asia Partners V, a $6.55 billion fund for buyout and strategic investments in the Asia-Pacific region.
MVM still holds a significant interest in Ambio Holdings.
The terms of the transaction were not disclosed.
The asset management firm had invested more than $11.5 billion in the global healthcare industry, with an estimated $1.5 billion spent on healthcare companies in Asia as of June 30.